ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

NTLA Intellia Therapeutics Inc

23.00
-0.88 (-3.69%)
Fuera de horario
Última actualización: 15:02:01
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Intellia Therapeutics Inc NTLA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.88 -3.69% 23.00 15:02:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
23.38 22.756 23.64 23.02 23.88
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202406:30GLOBEIntellia Therapeutics to Hold Conference Call to Discuss..
29/4/202406:30GLOBEIntellia Therapeutics to Present Updated Data from Phase 1/2..
18/3/202406:30GLOBEIntellia Therapeutics Announces First Patient Dosed in the..
05/3/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202406:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/2/202416:17EDGAR2Form 8-K - Current report
22/2/202415:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202415:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202406:45EDGAR2Form 8-K - Current report
22/2/202406:30GLOBEIntellia Therapeutics Announces Fourth Quarter and Full-Year..
15/2/202406:30BWIntellia Therapeutics and ReCode Therapeutics Announce..
14/2/202406:30GLOBEIntellia Therapeutics to Hold Conference Call to Discuss..
01/2/202415:05EDGAR2Form 8-K - Current report
31/1/202416:00GLOBEIntellia Therapeutics Announces Publication of Positive..
29/1/202415:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:05EDGAR2Form 144 - Report of proposed sale of securities
05/1/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:07EDGAR2Form 8-K - Current report
04/1/202415:01GLOBEIntellia Therapeutics Highlights its Three-Year Strategic..
03/1/202416:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202306:00EDGAR2Form 8-K - Current report
24/11/202308:30EDGAR2Form S-3ASR - Automatic shelf registration statement of..
14/11/202306:30GLOBEIntellia Therapeutics Receives European Union Orphan Drug..
09/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:45EDGAR2Form 8-K - Current report
09/11/202306:30GLOBEIntellia Therapeutics Announces Third Quarter 2023 Financial..
02/11/202315:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202306:11EDGAR2Form 8-K - Current report
02/11/202306:00GLOBEIntellia Presents New Interim Data from the Ongoing Phase 1..
26/10/202306:30GLOBEIntellia Therapeutics to Present Updated Data from Ongoing..
18/10/202306:30EDGAR2Form 8-K - Current report
18/10/202306:00GLOBEIntellia Therapeutics Announces FDA Clearance of..
13/10/202307:38GLOBEIntellia Therapeutics Receives Priority Medicines (PRIME)..
03/10/202306:19EDGAR2Form 8-K - Current report
03/10/202306:00GLOBERegeneron and Intellia Announce Expanded Research..
03/8/202315:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202306:45EDGAR2Form 8-K - Current report
03/8/202306:30GLOBEIntellia Therapeutics Announces Second Quarter 2023..
02/8/202316:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202315:45EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

Delayed Upgrade Clock